+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Circulating Tumor Cell (CTC) Diagnostics - Global Market Trajectory & Analytics

  • ID: 2832326
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • ApoCell, Inc.
  • Biocept, Inc.
  • Clearbridge Biomedics
  • Cynvenio Biosystems, Inc.
  • Ikonisys, Inc.
  • Janssen Diagnostics LLC
Global Circulating Tumor Cell (CTC) Diagnostics Market to Reach $19 Billion by 2027

Amid the COVID-19 crisis, the global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$19 Billion by 2027, growing at a CAGR of 17.3% over the analysis period 2020-2027. CTC Enrichment Methods, one of the segments analyzed in the report, is projected to record a 17.8% CAGR and reach US$9.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the CTC Detection Methods segment is readjusted to a revised 17% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.8 Billion, While China is Forecast to Grow at 16.6% CAGR

The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2027 trailing a CAGR of 16.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.4% and 14.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

CTC Analysis Segment to Record 16.3% CAGR

In the global CTC Analysis segment, USA, Canada, Japan, China and Europe will drive the 16.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.1 Billion in the year 2020 will reach a projected size of US$3.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.3 Billion by the year 2027.

Select Competitors (Total 48 Featured):
  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ApoCell, Inc.
  • Biocept, Inc.
  • Clearbridge Biomedics
  • Cynvenio Biosystems, Inc.
  • Ikonisys, Inc.
  • Janssen Diagnostics LLC
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Market Outlook
  • Recent Market Activity
  • Clinical Relevance of CTCs
  • CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy
  • Major Challenges in CTC Diagnostics
  • Need for CTC Enrichment and Popular Methods
  • CTC Enrichment Techniques
  • Select Available CTC Detection Technologies
  • Select CTC Isolation Systems - A Brief Comparison
  • CTC Identification - Various Approaches
  • CTC Identification Approaches
  • List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type
  • CellSearch System™ - The First FDA Approved Automated Enrichment/Isolation Technique
  • Rising Incidence of Cancer - An Opportunity Indicator
  • Cancer Prone Sites based on Age
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • ApoCell, Inc. (US)
  • Biocep Ltd. (Israel)
  • Biocept, Inc. (US)
  • Biofluidica Microtechnologies LLC (US)
  • Celltraffix Inc. (US)
  • Clearbridge Biomedics (Singapore)
  • Creatv Microtech, Inc. (US)
  • Cynvenio Biosystems, Inc. (US)
  • Epic Biosciences Inc. (US)
  • Fluxion Biosciences, Inc. (US)
  • Ikonisys, Inc. (US)
  • IVDiagnostics, Inc. (US)
  • Janssen Diagnostics LLC (US)
  • QIAGEN Hannover GmbH (Germany)
  • RARECELLS SAS (Italy)
  • ScreenCell (France)
  • STEMCELL Technologies, Inc. (Canada)
3. MARKET TRENDS & DRIVERS
  • Liquid Biopsy - the New Buzzword in Healthcare
  • Select Companies Active in Cancer Liquid Biopsy
  • CTCs for Personalized Cancer Treatment
  • Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis
  • CTC Microdevices Hog the Limelight
  • Increasing Research Reveal Further Complexities to CTC Composition and Behavior
  • EpCAM Glycoprotein - Insufficient for CTC Detection
  • New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs
  • Physical Property-based Enrichment Technologies Lose Fizz
  • Evidence in Favor CTC Heterogeneity Gains Strength
  • CTC Clusters Raise Research Interest
  • Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings
  • Limitations of CTC Technology for Point-of-Care Testing
  • CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
  • Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?
  • Select Research Findings in Recent Years
  • Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
  • NBiomics Makes its Contribution to CTC Diagnosis
  • Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
  • Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
  • Gold Nanoparticles Help in the Detection of CTCs
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for CTC Enrichment Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for CTC Enrichment Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for CTC Enrichment Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for CTC Detection Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for CTC Detection Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for CTC Detection Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for CTC Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for CTC Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for CTC Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Cancer Stem Cell Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Cancer Stem Cell Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Cancer Stem Cell Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for EMT Biomarkers Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for EMT Biomarkers Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for EMT Biomarkers Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Tumorgenesis Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Tumorgenesis Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Tumorgenesis Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 25: USA Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: USA 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 28: USA Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: USA 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
  • Table 31: Canada Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Canada 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 34: Canada Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Canada 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 37: Japan Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: Japan 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 40: Japan Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Japan 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
  • Table 43: China Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: China 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 46: China Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: China 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 49: Europe Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 50: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: Europe 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 52: Europe Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Europe 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 55: Europe Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Europe 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 58: France Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 59: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 60: France 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 61: France Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 63: France 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 64: Germany Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 65: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 66: Germany 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 67: Germany Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 69: Germany 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
  • Table 70: Italy Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 71: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 72: Italy 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 73: Italy Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 75: Italy 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 76: UK Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 77: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 78: UK 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 79: UK Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 80: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 81: UK 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 82: Rest of Europe Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 83: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 84: Rest of Europe 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 85: Rest of Europe Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 86: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 87: Rest of Europe 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 88: Asia-Pacific Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 89: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 90: Asia-Pacific 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 91: Asia-Pacific Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 92: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 93: Asia-Pacific 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 94: Rest of World Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 95: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - CTC Enrichment Methods, CTC Detection Methods and CTC Analysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 96: Rest of World 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for CTC Enrichment Methods, CTC Detection Methods and CTC Analysis for the Years 2012, 2020 & 2027
  • Table 97: Rest of World Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 98: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 99: Rest of World 15-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Cancer Stem Cell Research, EMT Biomarkers Development, Tumorgenesis Research and Other Applications for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 48
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll